Press Releases
GNS Healthcare Announces a Multi-Year Collaboration with a Leading US Cancer Center to Advance Precision Medicine in Oncology
Collaboration with Memorial Sloan Kettering Cancer Center’s Innovation Hub aims to answer key questions in prostate cancer patient care and accelerate discovery and development of new treatments Somerville, Mass.– October 5, 2021– GNS Healthcare (GNS), an artificial...
read moreGNS to Develop the World’s First in silico Patient For Prostate Cancer
Somerville, Mass., May 25, 2021: GNS Healthcare, an artificial intelligence company creating in silico patients that simulate drug treatment at the individual patient level, today announced plans to develop and launch Gemini — The in silico Patient™ for Prostate...
read moreGNS to Develop the World’s First in silico Patient For Prostate Cancer
Somerville, Mass., May 25, 2021: GNS Healthcare, an artificial intelligence company creating in silico patients that simulate drug treatment at the individual patient level, today announced plans to develop and launch Gemini — The in silico Patient™ for Prostate...
read moreGNS Healthcare Hires Alan Kilyk as Chief Financial Officer
Somerville, MA: GNS Healthcare, an AI company creating in silico patients to simulate disease progression and drug treatment at the individual patient level, is pleased to announce that accomplished finance executive Alan Kilyk has joined the company’s leadership team...
read moreQIAGEN Adopts GNS Healthcare’s Gemini – The in silico Patient™ Across Multiple Cancers
Partnership enables enhanced capability to discover new targets and prognostic markers Somerville, MA: GNS Healthcare, the leading AI-driven precision medicine company, today announced a partnership with QIAGEN, the leading global provider of Sample to Insight...
read moreGNS Healthcare Presents Novel Use of AI to Identify Drivers of Response to Immune Checkpoint Inhibitor Therapy
AI-driven in silico patients used to accurately identify types of immune responses in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC). CAMBRIDGE, Mass.– [July 21, 2020] – GNS Healthcare (GNS), a leading AI and simulation company,...
read moreGNS Healthcare Launches Gemini, the First In Silico Patient for Multiple Myeloma
A transformative innovation GeminiTM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma GNS Healthcare, an AI-driven precision medicine company, today announced the launch of...
read moreGNS Healthcare Launches Gemini, the First In Silico Patient for Multiple Myeloma
A transformative innovation GeminiTM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma GNS Healthcare, an AI-driven precision medicine company, today announced the launch of...
read moreGNS Healthcare and Multiple Myeloma Research Foundation (MMRF) Announce a Five-Year Collaboration to Advance Precision Medicine
Partnership Aims to Answer Key Questions in Multiple Myeloma Patient Care and Accelerate Discovery and Development of New Treatments Cambridge, MA – June 18, 2020-- GNS Healthcare and the Multiple Myeloma Research Foundation (MMRF) today announced a five-year...
read moreGNS Healthcare and Collaborators Identify PHF19 as Marker of Aggressive Multiple Myeloma Progression
Study results are from the DREAM Challenge and are published in Leukemia CAMBRIDGE, Mass.– May 28, 2020 – GNS Healthcare (GNS), a leading AI-driven precision medicine, announced results of a recently published collaboration that uncovered transcription factor PHF19 as...
read more